The global hemostasis and tissue sealing agents market is anticipated to grow at a CAGR of 9.3% during the forecast period (2023-2030). The treatment of chronic diseases leads to in the patient undergoing surgery, which drive the market growth. Urological disorders, Hernia fixation, spinal injuries, diabetes, burns, and ophthalmic injuries and replacements, are a few chronic conditions requiring these products. According to the WHO, an estimated 180,000 deaths every year are caused by burns. The vast majority occur in low- and middle-income countries. In India, over 1 million people are moderately or severely burnt every year. Further, United Spinal Association, in July 2022, every year approximately 17,700 Americans acquire a spinal cord injury. Roughly 78% are men, and their average age is 43. Most spinal cord injuries happen because of a vehicle accident (39.3%), followed closely by falls (31.8%), trailed by violence (13.2%), sports (8%), and medical/surgery (4.3%). As per the American Academy of Ophthalmology Study 2023, a new study found that hospitalizations of people who had eye trauma rose by 18% over 13 years. Most of the increase was due to falls among people over age 65.
Browse the full report description of “Hemostasis and Tissue Sealing Agents Market Size, Share & Trends Analysis Report by Product (Topical Hemostat, Adhesive and Tissue Sealant), by Material (Collagen-based Topical Hemostats, Gelatin based Topical Hemostats, ORC-based Topical Hemostats and Polysaccharide based Topical Hemostats), by Application (General Surgery, Minimally Invasive Surgery, Trauma and Other Applications), by End-Use (Hospitals and Ambulatory Surgical Centers), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/hemostasis-and-tissue-sealing-agents-market
Owing to these factors, the manufacturers are compelled to develop the products o cater the market growth. In December 2019, Johnson & Johnson Medical Devices Companies Ethicon, Inc., launched the VISTASEAL™ Fibrin Sealant (Human) to manage bleeding during surgery. VISTASEAL Fibrin Sealant (Human) contains a combination of fibrinogen and thrombin, clotting proteins found in human plasma. When applied to the bleeding site, it forms a rapid, adherent, and durable clot and has been demonstrated to sustain hemostasis, even in high-risk patients. In three randomized controlled trials, VISTASEAL was associated with a lower overall hemostatic retreatment rate (0.9%-7.8%) compared to standard treatments (8.0%-16.7%).
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Product
o By Material
o By Application
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- includes Baxter International, Inc., Becton, Dickinson & Co., Johnson & Johnson Medical NV, Medtronic Plc., Pfizer, Inc., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Hemostasis and Tissue Sealing Agents Market Report Segment
By Product
By Material
By Application
By End-User
Global Hemostasis and Tissue Sealing Agents Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hemostasis-and-tissue-sealing-agents-market